Molecular Pharming - Global Strategic Business Report

The global market for Molecular Pharming was estimated at US$1.7 Billion in 2024 and is projected to reach US$2.3 Billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Molecular Pharming market.

Global Molecular Pharming Market - Key Trends & Drivers Summarized

What Is Molecular Pharming and Why Is It Gaining Momentum?

Molecular pharming refers to the use of genetically modified plants to produce pharmaceutical substances such as vaccines, antibodies, enzymes, and therapeutic proteins. This technique combines plant biotechnology with pharmaceutical manufacturing, allowing plants to function as biofactories for complex biologics. Molecular pharming is gaining attention for its potential to offer scalable, low-cost, and contamination-resistant alternatives to traditional cell-based or microbial production systems.

By using crops such as tobacco, maize, rice, and even lettuce, researchers can express specific genes that encode therapeutic proteins. These proteins are then harvested and purified for medical use. Molecular pharming is particularly suited for producing biologics in large volumes, especially in low-resource settings or during health emergencies where rapid and cost-effective manufacturing is critical. Its growing relevance lies in its ability to meet rising global demand for biologics while bypassing the limitations of conventional production infrastructure.

How Are Technologies and Processes Advancing in This Field?

Advancements in genetic engineering, plant transformation techniques, and protein expression systems have significantly improved the efficiency and viability of molecular pharming. Technologies such as Agrobacterium-mediated gene transfer, transient expression using viral vectors, and CRISPR-based gene editing are helping optimize yields and reduce development time. Purification processes have also evolved, with new methods enabling the recovery of high-purity proteins without damaging their structure or function.

Innovations now allow expression of monoclonal antibodies, insulin analogs, and enzyme replacement therapies directly within plant tissues. Some approaches use hydroponically grown plants in contained environments to maintain consistency and meet pharmaceutical-grade standards. Regulatory frameworks are gradually adapting to support commercial scale-up, with a few plant-derived biologics already approved for use. These developments are expanding confidence in plant-based production systems, especially for niche or high-volume therapeutic needs.

Where Is Molecular Pharming Being Applied and Who Are the Key Stakeholders?

Molecular pharming is being applied in several areas including vaccine development, infectious disease treatment, cancer therapy, and rare genetic disorders. One of its major successes has been the production of antibodies against Ebola and rabies viruses. Research institutions, biotech firms, and pharmaceutical companies are investing in plant-based platforms to diversify their biologics pipelines and respond to evolving global health priorities.

Academic research centers play a central role in early-stage development and proof-of-concept studies, while private-sector players focus on scale-up, formulation, and regulatory approval. Governments and health organizations in developing regions view molecular pharming as a means to achieve greater self-reliance in essential medicine production. Partnerships between public institutions and biotech companies are becoming more common, especially for producing vaccines and treatments for diseases that lack commercial incentives under traditional models.

What Factors Are Driving Growth In The Molecular Pharming Market?

Growth in the molecular pharming market is driven by several factors including rising demand for biologics, limitations of traditional manufacturing systems, and the need for flexible, scalable production platforms. Molecular pharming offers cost advantages in terms of infrastructure and raw materials, making it attractive for producing affordable therapies in developing countries. The ability to rapidly deploy production in response to emerging infectious diseases is another key benefit driving interest.

Advances in plant biotechnology, increased investment in synthetic biology, and progress in downstream purification technologies are helping overcome past limitations related to yield and consistency. Growing support from regulatory bodies and public health institutions is also encouraging wider adoption. As global healthcare systems look for resilient and decentralized manufacturing solutions, molecular pharming is emerging as a viable approach to meeting future therapeutic needs with greater speed and sustainability.

Scope Of Study:

The report analyzes the Molecular Pharming market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Crop Source (Maize Crop, Barley Crop, Tobacco Crop, Safflower Crop, Rice Crop, Alfalfa Crop); Technology (Gene Gun Technology, Agro infiltration Technology, Electroporation Technology, Agrobacterium-Mediated Gene Transfer Technology, Other Technologies); Application (Recombinant Antibodies Application, Hormones Application, Vaccines Application, Industrial Enzymes Application, Proteins & Protein-based Materials Application, Technical Reagents Application, Other Applications); End-Use (Biotech & Pharma Companies End-Use, CROs End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Maize Crop segment, which is expected to reach US$607.4 Million by 2030 with a CAGR of a 5.0%. The Barley Crop segment is also set to grow at 4.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $449.8 Million in 2024, and China, forecasted to grow at an impressive 9.1% CAGR to reach $468.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Molecular Pharming Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Molecular Pharming Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Molecular Pharming Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Agrenvec S.L., Avaxin Biologics, Baiya Phytopharm, BioBetter Ltd., Bright Biotech and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 39 companies featured in this Molecular Pharming market report include:

• Agrenvec S.L.
• Avaxin Biologics
• Baiya Phytopharm
• BioBetter Ltd.
• Bright Biotech
• Cape Bio Pharms (Cape Biologix Tech.)
• Diamante S.r.l.
• Elo Life Systems
• Leaf Expression Systems
• Medicago Inc.
• Miruku
• Moolec Science SA
• MOZZA (Mozza Foods)
• Nobell Foods
• ORF Genetics hf.
• PlantForm Corporation
• Planet Biotechnology Inc.
• ProdiGene Inc.
• Protalix Biotherapeutics, Inc.
• Tiamat Sciences Corp.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.